Publications
Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J. and Cantley, L.C. (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway. Molecular Cell 10, 151-162.6.
Tee, A.R., Fingar D.C., Manning, B.D., Kwiatkowski, D.J., Cantley L.C., and Blenis, J. (2002) Tuberous sclerosis complex-1 and –2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. PNAS 99, 13571-13576.
Manning, B.D. and Cantley, L.C. (2002) Hitting the target: emerging technologies in the search for kinase substrates. Science STKE pe49.
Manning, B.D., Cantley, L.C. (2003) United at last: the tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochemical Society Transactions 31, 573-8.
Tee, A.R., Manning, B.D., Roux, P.P., Cantley, L.C., and Blenis, J. (2003) Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex towards Rheb. Current Biology 13, 1259-1268.
Luo, J., Manning, B.D., and Cantley, L.C. (2003) Targeting the PI3K-Akt pathway in human cancers: rationale and promise. Cancer Cell 4, 257-262.
Manning, B.D. and Cantley, L.C. (2003) Rheb fills a GAP between TSC and TOR. Trends in Biochemical Sciences 28, 573-576.
Shaw, R.J., Bardeesy, N., Manning, B.D., Lopez, L., Kosmatka, M., DePinho, R.A., and Cantley, L.C. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99.
Brugarolas, J., Lei, K., Hurley, R.L., Manning, B.D., Reiling, J.H., Hafen, E., Witters, L.A., Ellisen, L.W., and Kaelin, W.G. (2004) Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes & Development 18, 2893-2904.
Manning, B.D. (2004) Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. Journal of Cell Biology 167, 399-403.
Manning, B.D., Logsdon, M.N., Lipovsky, A.I., Abbott, D., Kwiatkowski, D.J., and Cantley, L.C. (2005) Feedback inhibition of Akt signaling limits the growth of tumors lacking TSC2. Genes & Development 19, 1773-1778.
Kwiatkowski, D.J. and Manning, B.D. (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Human Molecular Genetics 15, R251-258.
Sodhi, A., Chaisuparat, R., Hu, J., Ramsdell, A.K., Manning, B.D., Sausville, E.A., Sawai, E.T., Molinolo, A., Gutkind, J.S. and Montaner, S. (2006) The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi’s Sarcoma Associated Herpesvirus G Protein-Coupled Receptor. Cancer Cell 10, 133-143.
Zhang, H.H., Lipovsky, A.I., Dibble, C.C., Sahin, M., and Manning, B.D. (2006) S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Molecular Cell 24, 185-197.
Manning, B.D. and Cantley, L.C. (2007) AKT/PKB signaling: Navigating downstream. Cell 129, 1261-1274.
Ozcan, U., Ozcan, L., Yilmaz, E., Duvel, K., Sahin, M., Manning, B.D., and Hotamisligil, G.S. (2008) Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Molecular Cell 29, 541-551.
Huang J, Manning BD. (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochemical Journal 412, 179-90.
Huang J, Dibble CC, Matsuzaki M, and Manning BD. (2008) The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Molecular and Cellular Biology 28, 4104-4115.